Metformin is not an SGLT2 inhibitor. These are two completely different classes of diabetes medication that work through different mechanisms in different parts of the body. Metformin primarily acts on the liver, while SGLT2 inhibitors work in the kidneys. They are, however, frequently prescribed together, which may be why the two get confused.
How Metformin Works
Metformin belongs to a drug class called biguanides. Its primary job is reducing the amount of glucose your liver releases into your bloodstream. Your liver naturally stores sugar and dumps it into your blood between meals, but in type 2 diabetes, this process goes into overdrive. Metformin dials it back. It also helps your body’s cells respond better to insulin, so the sugar already in your blood gets used more efficiently.
At a cellular level, metformin works by influencing energy metabolism. It activates an energy-sensing enzyme called AMPK, which signals the liver to slow down glucose production. This is an entirely internal process: metformin changes how your body handles the sugar it already has, rather than removing sugar from the body.
How SGLT2 Inhibitors Work
SGLT2 inhibitors take a fundamentally different approach. SGLT2 (sodium-glucose transport protein 2) is a protein in your kidneys that recaptures glucose from urine and sends it back into your bloodstream. Under normal conditions, this is useful. In type 2 diabetes, it means your kidneys keep recycling sugar you’d be better off losing.
SGLT2 inhibitors block that recycling process. When the protein is blocked, glucose stays in your urine instead of returning to your blood, and you literally pee out excess sugar. This is a mechanical removal of glucose from the body, which is why the effect doesn’t depend much on how well your insulin is working.
The FDA-approved SGLT2 inhibitors include canagliflozin (Invokana), dapagliflozin (Farxiga), and empagliflozin (Jardiance). None of them are chemically or functionally related to metformin.
Key Differences at a Glance
- Drug class: Metformin is a biguanide. SGLT2 inhibitors are their own distinct class.
- Where they act: Metformin targets the liver. SGLT2 inhibitors target the kidneys.
- What they do to glucose: Metformin reduces how much glucose your liver produces. SGLT2 inhibitors cause your kidneys to excrete glucose in urine.
- Weight effects: SGLT2 inhibitors produce measurable weight loss, averaging about 1.88 kg (roughly 4 pounds) more than placebo in clinical trials. Metformin is considered weight-neutral or modestly weight-reducing.
- Extra benefits: SGLT2 inhibitors have demonstrated cardiovascular and kidney-protective effects beyond blood sugar control, including blood pressure reduction. Metformin has long been considered protective for the heart as well, though through different pathways.
Side Effects Differ Too
Because these drugs work on different organs, their side effects look nothing alike. Metformin is well known for causing gastrointestinal issues, especially nausea, diarrhea, and stomach discomfort, particularly when you first start taking it or when the dose increases. These effects usually improve over a few weeks, and extended-release versions tend to be gentler on the stomach.
SGLT2 inhibitors, because they increase sugar in the urine, create an environment where yeast and bacteria thrive. Genital yeast infections and urinary tract infections are the most common side effects. There’s also a small risk of dehydration, since these drugs increase how much fluid your kidneys release. Canagliflozin carries an FDA warning about an increased risk of leg and foot amputations, and both canagliflozin and dapagliflozin have strengthened kidney warnings from the FDA.
Why They’re Often Used Together
The confusion between these two medications likely stems from how often they’re prescribed as a pair. SGLT2 inhibitors are frequently combined with metformin, and several combination pills bundle both drugs into a single tablet (such as Invokamet, which combines canagliflozin with metformin, or Xigduo XR, which combines dapagliflozin with metformin).
The clinical logic is straightforward: because metformin and SGLT2 inhibitors lower blood sugar through completely independent mechanisms, using both covers two different pathways at once. A real-world study published in Clinical Therapeutics found that people started on both metformin and an SGLT2 inhibitor from the point of diagnosis had significantly better cardiovascular outcomes at three years compared to those on metformin alone. The metformin-only group had a 44% higher risk of mortality, a 13% higher risk of heart failure, and a 24% higher risk of hospitalization. These benefits held even when blood sugar control was similar between the two groups, suggesting the combination does more than just lower glucose.
Starting combination therapy early, rather than adding a second drug only after the first one proves insufficient, appears to offer meaningful advantages. Poor glucose control in the early months after a type 2 diabetes diagnosis is linked to worse long-term outcomes even if blood sugar improves later.
Which One Comes First
Metformin has been the standard first-line medication for type 2 diabetes for decades, largely because of its long safety record, low cost, and effectiveness. SGLT2 inhibitors are newer and typically more expensive, though their unique cardiovascular and kidney benefits have made them increasingly common as an early addition rather than a last resort. For people with existing heart failure or chronic kidney disease, an SGLT2 inhibitor may be prioritized regardless of blood sugar levels, because the organ-protective effects are valuable on their own.
If you’re taking metformin and your doctor adds an SGLT2 inhibitor, the two drugs complement each other without overlapping. They don’t compete for the same pathways, and their side effect profiles are distinct enough that combining them doesn’t typically amplify either drug’s downsides.